roche glp-1 ⚡️ 𝗥𝗼𝗰𝗵𝗲 𝗷𝘂𝘀𝘁 𝗽𝗼𝘀𝘁𝗲𝗱 𝗣𝗵𝗮𝘀𝗲 𝟮 𝗼𝗯𝗲𝘀𝗶𝘁𝘆 𝗱𝗮𝘁𝗮 𝘁𝗵𝗮𝘁 𝗿𝗶𝘃𝗮𝗹 𝗭𝗲𝗽𝗯𝗼𝘂𝗻𝗱... 𝗬𝗲𝗮𝗿𝘀 𝗹𝗮𝘁𝗲 𝘁𝗼 𝗮 $𝟭𝟬𝟬𝗕 𝗿𝗮𝗰𝗲. has released Phase 2 results for CT-388, a dual GLP-1/GIP injectable obesity Can Swiss pharma giant Roche

This impending patent cliff is a material headwind for Novo Nordisk, but price reductions will drive a substantial uplift in the volume of patients on injectable semaglutide, through preferential reimbursement (by state or PMI payors) and improved affordability for the self-pay segment

10.1016/j.obpill.2024.100127

adults (ages 18 to 91) led by the Kinsey Institute at Indiana University with DatingAdvice.com, GLP-1 users reported a wide range of physical, social, and psychological shifts they attributed to the drug

The Reward System Connection Here's where the neuroscience meets everything I teach about reward chemistry hijacking

And then it does more

It is common, usually manageable, and once you know what these drugs do, almost never mysterious